-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – mRNA-1045 in Respiratory Syncytial Virus (RSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - mRNA-1045 in Respiratory Syncytial Virus (RSV) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MRNA-1045 in Respiratory Syncytial Virus (RSV) Infections Drug Details:mRNA-1045 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMND-02 in Fibromyalgia (Fibromyalgia Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMND-02 in Fibromyalgia (Fibromyalgia Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMND-02 in Fibromyalgia (Fibromyalgia Syndrome) Drug Details:Dimethyltryptamine (BMND02) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sytalizumab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sytalizumab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sytalizumab in Solid Tumor Drug Details: Sytalizumab is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMND-03 in Addictive Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMND-03 in Addictive Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMND-03 in Addictive DisordersDrug Details:BMND-03 (DMT) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMND-06 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMND-06 in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMND-06 in ObesityDrug Details:BMND06 (mescaline) is under development for the treatment of inflammation and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMND-09 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMND-09 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMND-09 in Parkinson's DiseaseDrug Details:BMND-09 (mescaline) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMND-07 in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMND-07 in Major Depressive Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMND-07 in Major Depressive Disorder Drug Details:BMND-07 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept Biosimilar in Wet (Neovascular /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LJ-2698 in Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LJ-2698 in Glaucoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LJ-2698 in GlaucomaDrug Details:LJ-2698 (FM-101) is under development for the treatment of ocular hypertension, diabetic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASKG-712 in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASKG-712 in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ASKG-712 in Wet (Neovascular / Exudative) Macular Degeneration Drug...